“Targeted therapeutics for specific genomic alterations in Medulloblastoma are likely to have an increasing role in the treatment of children with Medulloblastoma…” says researchers who performed a study investigating genetic abnormalities that can be targeted with precision medicine.
Over 50% of all tested samples showed that genetic irregularities could influence how diseases are diagnosed and treated. The researchers believe that this knowledge will be a great utility in the future to help with treatment options for Medulloblastoma. With continued testing of these abnormalities, researchers could eventually bring these techniques into practice, which will improve tumor classification and personalized treatment options for these tumor patients.
To read more about this discovery, click here.